Trial Profile

Phase I Study of Relapsed CD30 Expressing Lymphoma Treated with CD30 CAR T Cells (RELY-30)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TT 11 (Primary) ; Cyclophosphamide; Fludarabine
Indications Hodgkin's disease; Non-Hodgkin's lymphoma
Focus Adverse reactions
Acronyms RELY-30

Most Recent Events

06 Mar 2023 Planned End Date changed from 1 Feb 2036 to 1 Feb 2040.
16 Dec 2022 Planned number of patients changed from 66 to 60.
20 Jul 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com